ClinicalTrials.gg
Status unknownNCT05499260Updated Aug 16, 2022

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants

A Phase 1 interventional study of CB03-154 and Placebo in Healthy Volunteers, sponsored by Shanghai Zhimeng Biopharma, Inc.. Status unknown at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-16.

Sponsored by Shanghai Zhimeng Biopharma, Inc. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2022, registered Aug 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Epilepsy.

Read the detailed description

The purpose of this study is to see how safe the study drug is and how well it is tolerated after dosing. The study will also test how the study drug is taken up and eliminated by the body. An additional part of the study is to look at how this could be changed by giving the study drug with food.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Shanghai Zhimeng Biopharma, Inc. is the lead sponsor of 11 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female 18 to 55 years of age, inclusive.
  2. Ability to understand and willingness to sign a written form.
  3. Healthy as determined by medical history, physical examination, laboratory parameters, vital signs, and at Screening and Check-in.
  4. (BMI) ≥18.0 to ≤32.0 kg/m2 and body weight >50 kg (males) or >45 kg (females) at Screening.
  5. If a female, must be:

    • , defined as amenorrhea for at least 12 months, and confirmed by serum follicle stimulating hormone (FSH) and estradiol levels at Screening, OR
    • Surgically sterile with a documented hysterectomy, partial hysterectomy, bilateral oophorectomy, or bilateral tubal ligation at least 6 months prior to Screening, OR
    • If of , sexually active females with male partners must be using an acceptable method of such as an intrauterine device, implant or contraceptive injection, or two forms of the following (e.g., diaphragm, cervical cap, oral, patch or vaginal hormonal contraceptive, condom, spermicide, or sponge) for the last three months, and agree to continue to use their method of birth control for the duration of the study and for a minimum of one complete menstrual cycle after study completion. If a female subject is abstinent, she must agree to use an acceptable form of birth control should she become sexually active during the study.
  6. If a female, must have a negative pregnancy test result at Screening and Check-in.
  7. If a male, if sexually active with a female partner of child-bearing potential and has not had a vasectomy, must agree to use a highly effective double barrier method of contraception as deemed appropriate by the Investigator and must not donate sperm during the study and for 3 months after the last dose of study drug.
  8. Non-smokers (including nicotine-containing products) for at least 6 continuous months prior to the first dose by subject report.
  9. Willingness and ability to comply with study procedures and follow-up examination.

Exclusion criteria

Exclusion Criteria:

  1. Reported history of or current medical illness including but not limited to cardiac, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurological (e.g. history of epileptic seizures), or psychiatric disease.
  2. Reported history or presence of pro-arrhythmic conditions, including a marked baseline prolongation of (i.e., repeated demonstration of a QTcF interval >450 milliseconds) or a history of additional significant risk factors for torsade de pointes (e.g., family history of long QT syndrome), including any evidence of QTcF prolongation at screening.
  3. Clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at Screening or Check-in as deemed by the Investigator.
  4. Systolic blood pressure > 140 mm Hg and/or diastolic blood pressure > 90 mm Hg at Screening, and determined by the Investigator to confer a safety risk to the subject. Blood pressure measurements may be repeated after at least 10 minutes of rest if initial values obtained at Screening or Check-in are exclusionary.
  5. Subjects with active pathogen infections or carrier including but not limited to testing positive at Screening for (HIV), surface antigen (HBsAg), or virus (HCV) antibody.
  6. Subjects with a positive test result for Coronavirus disease 2019 (COVID-19) at Check-in.
  7. Donated blood or blood product or had substantial loss of blood (more than 500 mL) within 3 months prior to Screening.
  8. Use of any prescription or non-prescription drugs (including vitamins and herbal supplements) within 7 days prior to the first dose of study drug and throughout the study. Use of the following medication will be allowed during the study: acetaminophen (up to 1000 mg per 24 hours at the discretion of the Investigator).
  9. Reported history and/or recent evidence (within 2 years prior to the Screening) of alcohol abuse (e.g., for females, 4 or more drinks during a single occasion, or 8 or more drinks per week, and for males, 5 or more drinks during a single occasion, or 15 or more drinks per week), or other drug/substance use disorder.
  10. Positive test result for alcohol and/or drugs of abuse at Screening or Check-in.
  11. Known allergy or to CB03-154 or any of of CB03-154 tablet formulation.
  12. Received an experimental drug or used experimental medical device within 3 months or within 10 half-lives of the drug, whichever is longer, prior to the first dose of study drug.
  13. Any condition or disorder that in the Investigators' opinion would put the subject or study conduct at risk if the subject were to participate in the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    CB03-154 SAD 5mg

    Participants will receive CB03-154 5mg orally once daily in a fasted state.

    Drug: CB03-154

  • Placebo comparator
    Placebo SAD 5mg

    Participants will receive placebo 5mg orally once daily in a fasted state.

    Drug: Placebo

  • Experimental
    CB03-154 SAD 10mg

    Participants will receive CB03-154 10mg orally once daily in a fasted state.

    Drug: CB03-154

  • Placebo comparator
    Placebo SAD 10mg

    Participants will receive placebo 10mg orally once daily in a fasted state.

    Drug: Placebo

  • Experimental
    CB03-154 SAD 20mg

    Participants will receive CB03-154 20mg orally once daily in a fasted state.

    Drug: CB03-154

  • Placebo comparator
    Placebo SAD 20mg

    Participants will receive placebo 20mg orally once daily in a fasted state.

    Drug: Placebo

  • Experimental
    CB03-154 SAD 40mg

    Participants will receive CB03-154 40mg orally once daily in a fasted state.

    Drug: CB03-154

  • Placebo comparator
    Placebo SAD 40mg

    Participants will receive placebo 40mg orally once daily in a fasted state

    Drug: Placebo

  • Experimental
    CB03-154 SAD 60mg

    Participants will receive CB03-154 60mg orally once daily in a fasted state.

    Drug: CB03-154

  • Placebo comparator
    Placebo SAD 60mg

    Participants will receive placebo 60mg orally once daily in a fasted state.

    Drug: Placebo

  • Experimental
    CB03-154 FE

    Participants will receive CB03-154 orally once daily in a fed state.

    Drug: CB03-154

  • Experimental
    CB03-154 MAD 10mg

    Participants will receive CB03-154 10mg orally once daily in a fasted state, for 14 consecutive days.

    Drug: CB03-154

  • Placebo comparator
    Placebo MAD 10mg

    Participants will receive placebo 10mg orally once daily in a fasted state, for 14 consecutive days.

    Drug: Placebo

  • Experimental
    CB03-154 MAD 20mg

    Participants will receive CB03-154 20mg orally once daily in a fasted state, for 14 consecutive days.

    Drug: CB03-154

  • Placebo comparator
    Placebo MAD 20mg

    Participants will receive placebo 20mg orally once daily in a fasted state, for 14 consecutive days.

    Drug: Placebo

  • Experimental
    CB03-154 MAD 40mg

    Participants will receive CB03-154 40mg orally once daily in a fasted state, for 14 consecutive days.

    Drug: CB03-154

  • Placebo comparator
    Placebo MAD 40mg

    Participants will receive placebo 40mg orally once daily in a fasted state, for 14 consecutive days.

    Drug: Placebo

Interventions

  • CB03-154 tablet once daily.

  • DrugPlacebo

    Placebo tablet once daily.

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of CB03-154 following single and multiple ascending oral dose administration.

    Number of participants with teatment-related adverse events as assessed by CTCAE V5.0 or higher

    Time frame: rom the signing of the consent form until 30 days following the last dose of the study drug

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of CB03-154

    Plasma will be collected at multiple timepoints from within 60 minutes pre-dose to 48 hours post-dose

    Time frame: From 1 hour pre-dose to 48 hours post-dose

  2. Area Under the Plasma Concentration Versus Time Curve (AUC) of CB03-154

    Plasma will be collected at multiple timepoints from within 60 minutes pre-dose to 48 hours post-dose

    Time frame: From 1 hour pre-dose to 48 hours post-dose

07

Study locations

1 of 1 sites recruiting
  • Frontage Clinical Services, Inc.
    Secaucus, New Jersey 07094, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for Mar 2023, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2022
First posted
Aug 12, 2022
StartActual
May 2, 2022
Primary completionEst.
Mar 2, 2023
CompletionEst.
Mar 2, 2023
Last update
Aug 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05499260
Lead sponsor
Shanghai Zhimeng Biopharma, Inc.
Responsible party
Sponsor
First posted
Aug 12, 2022
Start date
May 2, 2022
Primary completion
Mar 2, 2023 (estimated)
Completion
Mar 2, 2023 (estimated)
Last update
Aug 16, 2022

Study contacts

Peter Van Wie, PhD
Contact
PVanWie@frontagelab.com
(+1) 551-278-9723 ext. 121052
Annie Li, M.D
Contact
ali@frontagelab.com
(+1) 201-416-7770
Frank Lee, M.D
principal investigator · Frontage Clinical Services, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CB03-154

Start the discussion